Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gian Life CareBOM:542918 -0.41%59 PB Ratio is 0.27 as of Aug. 06, 2026, which is 82% below its 10-year median of 1.50. GuruFocus rates BOM:542918 with a GF Score™ of 59/100 and a GF Value™ of ₹5.88 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Gian Life Care ranks better than 97.95% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-06), Gian Life Care's share price is ₹4.91. Gian Life Care's Book Value per Share for the quarter that ended in Dec. 2025 was ₹18.15. Hence, Gian Life Care's PB Ratio of today is 0.27.
Good Sign:
Gian Life Care Ltd stock PB Ratio (=0.25) is close to 10-year low of 0.25.
The historical rank and industry rank for Gian Life Care's PB Ratio or its related term are showing as below:
BOM:542918'
s PB Ratio Range Over the Past 10 Years
Min: 0.25 Med: 1.5 Max: 7.24
Current: 0.26
During the past 7 years, Gian Life Care's highest PB Ratio was 7.24. The lowest was 0.25. And the median was 1.50.
BOM:542918's PB Ratio is ranked better than 97.95% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs BOM:542918: 0.26
During the past 12 months, Gian Life Care's average Book Value Per Share Growth Rate was 81.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.30% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Gian Life Care was 460.60% per year. The lowest was 11.10% per year. And the median was 25.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gian Life Care PB Ratio Related Terms
Gian Life Care PB Ratio Historical Data
* Premium members only.
The historical data trend for Gian Life Care's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Gian Life Care's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gian Life Care PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Gian Life Care's PB Ratio distribution charts can be found below:
* The bar in red indicates where Gian Life Care's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Gian Life Care's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gian Life Care (BOM:542918) has a PB Ratio of 0.27 as of Aug. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gian Life Care and its competitors. This is 82% below median its historical median of 1.50. Over the past decade, Gian Life Care's PB Ratio has ranged from 0.25 to 7.24. According to the industry distribution chart, Gian Life Care ranks #4 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 2.1%.
Is Gian Life Care's PB Ratio too high?
Gian Life Care's current PB Ratio of 0.27 is 82% below median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 7.24. The Medical Diagnostics & Research industry median PB Ratio is 2.06. Gian Life Care's value of 0.27 is 86.9% below this industry median. Based on the distribution chart, Gian Life Care ranks #4 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Gian Life Care ranks #4 out of 195 companies for PB Ratio. This places Gian Life Care in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.06. Gian Life Care's value of 0.27 is 86.9% below this benchmark. Historically, Gian Life Care's own PB Ratio has ranged from 0.25 to 7.24 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 2.06, Gian Life Care has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.06, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gian Life Care's current PB Ratio of 0.27 is 86.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gian Life Care and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gian Life Care's current PB Ratio is 0.27, which is 82% below median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.88, compared to a current price of ₹4.91 — trading 16.5% below its estimated fair value. The current PB Ratio is 0.27, which is 82% below median its 10-year median of 1.50 and 86.9% below the Medical Diagnostics & Research industry median of 2.06. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current PB Ratio is 0.27 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.91 is trading 16.5% below its estimated GF Value™ of ₹5.88.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
PB Ratio: 0.27 (82% below median its 10-year median of 1.50)
GF Value™: ₹5.88 vs. price of ₹4.91 (16.5% below fair value)
Industry Position: 86.9% below the Medical Diagnostics & Research median (#4 of 195)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
